Abstract: A long-established hypothesis is that schizophrenia has a strong genetic component. In the early 1990s, the first genetic variant that substantially increases risk for psychosis was identified. Since this initial reporting of deletions in the chromosomal region 22q11.2, nearly two decades passed until substantial insights into schizophrenia's genetic architecture were gained. Schizophrenia is a polygenic disorder and genetic risk is conferred by both common and rare alleles distributed across the genome. A small number of rare, deleterious copy number variants (CNVs) are associated with moderate to substantial increases in individual risk to schizophrenia. These deletions and duplications are also associated with a range of neurodevelopmental disorders. The diagnostic investigation of CNVs in patients with schizophrenia is likely to represent one of the first examples of genetic testing in clinical psychiatry. The prerequisites for this are currently being defined.

Keywords: intellectual disability, autism spectrum disorders, SETD1A, genome-wide genotyping array

Introduction

Schizophrenia is a severe neuropsychiatric disorder with a lifetime prevalence of ~1%. Patients with schizophrenia display a broad range of symptoms which include hallucinations, delusions, disorganized speech and/or behavior, and negative symptoms such as a blunted affect [1]. Schizophrenia is a clinical diagnosis and currently there is no single clinical or laboratory test available to confirm or rule out the diagnosis. Patients are offered a multiprofessional treatment that includes antipsychotic medication, psychoeducation, and psychotherapy [2]. Schizophrenia is a multifactorial disorder with both genetic and environmental factors contributing to its development. The genetic component is strong. Heritability estimates range between 60–80% [3, 4]. In the early 1990s, deletions in the chromosomal region 22q11.2 were identified to substantially increase the risk for psychosis [5]. Since the reporting of this first unequivocal genetic risk factor for schizophrenia, nearly two decades passed before substantial insights into disease-relevant biological mechanisms were gained [6–12]. The present article provides a concise overview of the current understanding of the genetic architecture of schizophrenia.

Complex genetic architecture

In the 1990s and early 2000s, numerous schizophrenia candidate gene studies were conducted with limited success. Major technological advances (e.g., cost-effective array-based genome-wide genotyping and next-generation sequencing technologies), deciphering the sequence of the human genome, and the successful establishment of international science consortia (e.g., Psychi-
Genomic loci. Of these loci, 75% included protein coding genes [11, 16]. Even though each identified variant conveys only a small risk, the study provides important insight into the biological underpinnings of schizophrenia. Associations were enriched for brain-expressed genes and genes expressed in tissues relevant for immunity. The latter, together with the strongest association signal being located in the MHC region, supports the hypothesized link between schizophrenia and the immune system [11].

Furthermore, associations in several genes relevant for glutamatergic neurotransmission and the DRD2 gene point to well-established and potentially new therapeutic drug targets. The DRD2 gene encodes the dopamine D2 receptor, which is the therapeutic target of antipsychotic medication [11, 16]. Additional notable associations include genes relevant for glutamatergic neurotransmission, synaptic plasticity, and genes encoding voltage-gated calcium channel subunits [11].

In a subsequent GWAS (currently the largest genetic study of schizophrenia), data from more than 5,000 patients with schizophrenia and 18,000 controls were combined with independent data from the PGC. A total of 179 genome-wide significant SNPs located in 145 loci were identified. Of these, 50 associated loci were novel and 93 were genome-wide significant in the GWAS previously published by the PGC [16, 17]. The association signal was highly enriched among loss-of-function (LoF) intolerant genes. Systems genomics analyses highlighted six gene sets that were independently associated with schizophrenia. These gene sets included (i) targets of the fragile X mental retardation protein (FMRP), (ii) abnormal behavior, (iii) abnormal nervous system electrophysiology, and (iv) voltage-gated calcium channel complexes [17].

Calculating polygenic risk scores (PRS) in order to stratify patients (e.g., in terms of course of disorder, prognosis, or treatment response) has gained traction [18]. PRS are a tool designed to capture the cumulative effects of numerous genetic loci into a single quantitative metric [19]. They are calculated using the weighted sum of the number of risk alleles carried by an individual. The risk alleles and their weights are derived from GWAS [18]. Currently, data on their potential use in clinical psychiatry are ambiguous [19–22]. Using PRS in a clinical setting is not recommended (https://ispg.net/genetic-testing-statement/). Large-scale, multi-ethnic studies are essential prior to considering the application of PRS in a non-research context [20, 22, 23]. However, PRS are an important research tool as they provide important insights into phenotypic correlations and inform research, e.g., on psychiatric endophenotypes [19].

Copy number variants are relevant in a subset of patients

In the early 1990s, deletions in the chromosomal region 22q11.2 were reported to substantially increase the risk for psychosis [5]. The identification of additional risk-associated CNVs was hampered by limited sample sizes. In 2017, the worldwide largest schizophrenia CNV analysis to date (21,000 patients with schizophrenia and 20,000 controls) identified genome-wide significant evidence for deletions and duplications in eight loci: 1q21.1, 2p16.3, 3q29, 7q11.2, 15q13.3, distal 16p11.2, proximal 16p11.2, and 22q11.2. The CNVs have moderate to substantial effect sizes (odds ratio ~4–65). Approximately 1% of patients were reported to carry one of these deleterious deletions/duplications. Suggestive evidence was identified for eight additional susceptibility and protective loci [9]. The identified CNVs are pleiotropic; for carriers of the schizophrenia-associated deletions and duplications, the risk of developing any childhood-onset neurodevelopmental disorder is significantly higher than the risk of developing schizophrenia [24, 25]. Some of the schizophrenia-associated CNVs alter fecundity [26]. The decrease in the number of offspring in the CNV carriers correlates highly
with the penetrance of the deletions and duplications associated with neurodevelopmental disorders [26, 27]. One hypothesis is that unaffected (no diagnosis of a neurodevelopmental disorder) CNV carriers have deficits in socializing and forming families, likely due to behavioral, cognitive, and medical issues [27].

A study conducted in the UK Biobank showed that the schizophrenia-associated CNVs are associated with some degree of cognitive impairment, even among individuals without a neurodevelopmental disorder (including schizophrenia). The reduction in cognitive performance may be subtle. However, CNV carriers had significant disadvantages in educational attainment and hence the ability to earn income in adult life compared with non-CNV carriers [27]. Furthermore, CNVs have a profound impact on medical health and mortality. This includes hypertension, obesity, diabetes mellitus, and renal failure. Clinicians need to plan their patients’ medical management accordingly, even in apparently unaffected CNV carriers [28].

As expected, the diagnostic yield for deleterious CNVs substantially increases in patients with a “syndromic form of psychiatric illness,” i.e., in patients with a dual diagnosis of schizophrenia and intellectual disability (ID)/autism spectrum disorder (ASD) [29–33]. Recently, the first study attempting to identify phenotypic information that might flag patients with schizophrenia as carriers of pathogenic CNVs was published. The authors had access to phenotype data that were collected using standard clinical assessments. Clinical features that successfully modeled positive CNV carrier status were (i) having a history of a specific learning disability such as dyslexia, dyscalculia, or dysgraphia; (ii) a history of developmental delay; and (iii) a comorbid neurodevelopmental diagnosis such as ASD, ID, or epilepsy [24].

With the exception of CNVs in 2p16.3 (NRXN1), the schizophrenia-associated deletions and duplications span multiple genes. Next-generation sequencing facilitates the analysis of smaller CNVs and their relevance to psychiatric disorder [34].

Exome sequencing provides further insights

Next-generation sequencing, currently predominantly exome sequencing, provides further insights into the biological mechanisms underlying schizophrenia. Patients with schizophrenia have an increased burden of ultra-rare, putatively protein damaging variants compared with controls [7]. Furthermore, patients have an increased burden of de novo LoF variants [7, 12, 16]. The rare coding variants are enriched in specific gene pathways, e.g., in synaptic function [6, 7, 10, 16]. The pathogenic variants detected among patients with schizophrenia overlap with pathogenic variants reported for ASD and ID [6].

The first (and currently only) gene to be implicated in schizophrenia at Bonferroni-corrected genome-wide levels of statistical significance is SETD1A. Rare LoF variants were strongly associated with schizophrenia in a study comprising more than 7,000 patients and 13,000 controls. Interestingly, seven of the ten patients with schizophrenia carrying an LoF variant were reported to have learning difficulties. The gene SETD1A encodes one of the methyltransferases that catalyze the methylation of lysine residues in histone H3. This supports the hypothesis that chromatin remodeling is an important molecular mechanism in the pathogenesis of schizophrenia [12].

Furthermore, exome sequencing facilitates the identification of inborn errors of metabolism (IEM). There is an increasing awareness that IEM might manifest beyond early childhood with psychiatric symptoms as the first indicator of the disorder. Targeted sequencing of genes relevant for IEM or exome sequencing might be warranted in patients with early onset psychosis [35, 36].

Future challenges and perspectives

Despite major breakthroughs, the identified variants account only for part of schizophrenia’s heritability, with approximately 20–30% of variance explained [9, 11, 17]. Historically large sample sizes are essential to further unravel the genetic underpinnings of schizophrenia [15, 37]. The recruitment of individuals is an ongoing international effort. It includes sampling a diverse range of ancestries (identification of new genetic associations due to different genetic architectures between populations) and using new ascertainment strategies (e.g., linking electronic health records to genomic data) [15, 37–39].

Gene–environment interactions might partially explain schizophrenia’s missing heritability. Genetic liability to schizophrenia might cause individuals to be more sensitive to environmental exposures or to have higher exposure rates [40]. Assessing the role of environmental factors in moderating genetic vulnerability is gaining traction and large cohorts with rich information on environmental exposures are being collected [41, 42]. The EUropean Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EUGEI) study provided
 evidence for an additive interaction between schizophrenia PRS and, e.g., exposure to early-life adversities and the presence of lifetime regular cannabis use [41]. Supplementing the available genetic data with genome-wide methylation data will provide further insights into the biological mechanisms underlying schizophrenia.

For the vast majority of identified variants, it is not known how they confer risk to schizophrenia. A broad range of methods is used to elucidate the molecular and cellular mechanisms relevant for the pathogenesis of schizophrenia [38]. These include genome editing in model organisms and human-induced pluripotent stem cell technology [43, 44].

Large-scale genetic studies demonstrated shared genetic risk across psychiatric disorders. Common variant analyses provided strong evidence particularly for genetic overlap between schizophrenia and bipolar disorder [8, 45, 46]. The identified risk variants aggregate in specific pathways such as histone methylation processes, postsynaptic density, and multiple neuronal and immune signaling pathways. The implicated pathways are shared between disorders [47]. Rare variant studies showed shared genetic risk between schizophrenia and neurodevelopmental disorders such as ASD and ID [6, 7, 12, 30, 31, 48]. Future research projects need to integrate communities researching childhood-onset neurodevelopmental disorders and adult-onset psychiatric disorders [16].

The diagnostic investigation of CNVs in patients with schizophrenia is likely to represent one of the first examples of genetic testing in clinical psychiatry. The prerequisites for this are currently being defined on both a European (EnGagE Network, Enhancing Psychiatric Genetic Counselling, Testing, and Training in Europe; CA17130, www.cost.eu/actions/CA17130) and an international level (Genetic Testing Committee of the International Society of Psychiatric Genetics; www.ispg.net/).

While anticipating the publication of the first recommendation for genetic testing in patients with schizophrenia (e.g., in patients with a history of developmental delay, early-onset psychosis, or treatment-resistant psychosis), the consensus statement on the genetic work-up of patients with ID and/or ASD await implementation into routine psychiatric care [49]. While in most European countries chromosomal microarrays and/or exome sequencing are standard of care for children with these diagnoses, diagnostic genetic testing is rarely offered to adult patients with neurodevelopmental disorders.

Identifying a deleterious CNV in an adult patient with a syndromic form of psychosis might inform clinical management [50, 51, 62]. For example, patients with a 22q11.2 deletion are at increased risk for serious adverse events to clozapine treatment and have a lowered seizure threshold. Medication (e.g., anticonvulsants) might exacerbate hypocalcemia [51–53]. Offering genetic testing to adult patients with impaired cognition will challenge the genetic counseling process [54]. More studies are warranted on factors influencing the phenotype expression and penetrance of the identified deleterious CNVs [27, 55–59]. Furthermore, case reports and case series containing both a comprehensive initial assessment of the patient with a psychiatric disorder and a systematic description of the longitudinal course and the impact of therapeutic efforts are warranted [60]. Interdisciplinary clinical management in centers for rare disorders with psychiatric manifestations is anticipated.

An improved understanding of the genetic architecture of schizophrenia and its underlying biological mechanisms will further facilitate patient stratification. Genotype-targeted treatment might improve patient care [61].

Conclusions and implications for clinical practice

- Schizophrenia is a genetically heterogeneous disorder. Large-scale studies have provided substantial insight into the disorder’s complex genetic architecture.
- For the majority of patients with schizophrenia, common variants are the main genetic contributor to the disorder. Currently, polygenic risk scores have no clinical utility.
- A subset of patients carry rare deleterious copy number variants (CNVs) with larger effect sizes. These CNVs are also associated with neurodevelopmental disorders such as intellectual disability (ID) and autism spectrum disorder (ASD).
- Genome-wide CNV testing should be offered to patients with schizophrenia and ID/ASD/organ malformations. Efforts to establish genetic testing in clinical psychiatry are under way.
- Patients and their family members tend to overestimate the recurrence risks for psychiatric disorders. Genetic counseling might be particularly useful in multiplex families with psychiatric (and) neurodevelopmental disorders.

Conflict of interest: F. Degenhardt states that there are no conflicts of interest.
References

[1] American Psychiatric Association, DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5™. 5th ed. American Psychiatric Publishing, Inc; 2013.

[2] Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde. S3 Leitlinie Schizophrenie; 2019. https://www.awmf.org/leitlinien/detail/I/038-009.html. Zugriffen: 07.04.2020.

[3] Pettersson E, Lichtenstein P, Larsson H et al. Genetic influences on eight psychiatric disorders based on family data of 4 408 646 full and half-siblings, and genetic data of 333 748 cases and controls. Psychol Med. 2019;49:1166–73.

[4] Wray NR, Gottesman II. Using summary data from the Danish national registers to estimate heritabilities for schizophrenia, bipolar disorder, and major depressive disorder. Front Genet. 2012;3:118.

[5] Karayiorgou M, Morris MA, Morrow B et al. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc Natl Acad Sci USA. 1995;92:7612–6.

[6] Fromer M, Pocklington AJ, Kavanagh DH et al. De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014;506:179–84.

[7] Genovese G, Fromer M, Stahl EA et al. Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia. Nat Neurosci. 2016;19:1433–41.

[8] International Schizophrenia Consortium, Purcell SM, Wray NR. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748–52.

[9] Marshall CR, Howrigan DP, Merico D et al. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nat Genet. 2017;49:27–35.

[10] Purcell SM, Moran JL, Merico D et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature. 2014;506:185–90.

[11] Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–7.

[12] Singh T, Kurki MI, Curtis D et al. Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. Nat Neurosci. 2016;19:571–7.

[13] Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860.

[14] Sullivan PF. The psychiatric GWAS consortium: big science comes to psychiatry. Neuron. 2010;68:182–6.

[15] Sullivan PF, Agrawal A, Bulik CM et al. Psychiatric Genomics: An Update and an Agenda. Am J Psychiatr. 2018;175:15–27.

[16] Owen MJ, O’Donovan MC. Schizophrenia and the neurodevelopmental continuum: evidence from genomics. World Psychiatry. 2017;16:227–35.

[17] Pardiñas AF, Holmans P, Pocklington AJ et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet. 2018;50:381.

[18] Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet. 2018;19:581–90.

[19] Fullerton JM, Nurnberger JL. Polygenic risk scores in psychiatry: Will they be useful for clinicians? F1000Res. 2019 Jul 31; 8. pii: F1000 Faculty Rev-1293; 2019.

[20] Legge SE, Dennison CA, Pardínas AF et al. Clinical indicators of treatment-resistant psychosis. Br J Psychiatr [Epub ahead of print]. 2019.

[21] Mistry S, Harrison JR, Smith DJ et al. The use of polygenic risk scores to identify phenotypes associated with genetic risk of schizophrenia: Systematic review. Schizophr Res. 2018;197:2–8.

[22] Vassos E, Di Forti M, Coleman J et al. An Examination of Polygenic Score Risk Prediction in Individuals With First-Episode Psychosis. Biol Psychiatry. 2017;81:470–7.

[23] Nóthen MM, Degenhardt F, Forstner AJ. Breakthrough in understanding the molecular causes of psychiatric disorders. Nervenarzt. 2019;90:99–106.

[24] Foley C, Heron EA, Harold D et al. Identifying schizophrenia patients who carry pathogenic genetic copy number variants using standard clinical assessment: retrospective cohort study. Br J Psychiatry. 2020;1–5.

[25] Kirov G, Rees E, Walters JT et al. The penetrance of copy number variations for schizophrenia and developmental delay. Biol Psychiatry. 2014;75:378–85.

[26] Stefansson H, Meyer-Lindenberg A, Steinberg S et al. CNVs conferring risk of autism or schizophrenia affect cognition in controls. Nature. 2014;505:361–6.

[27] Kendall KM, Bracher-Smith M, Fitzpatrick H et al. Cognitive performance and functional outcomes of carriers of pathogenic copy number variants: analysis of the UK Biobank. Br J Psychiatry. 2019;214:297–304.

[28] Crawford K, Bracher-Smith M, Owen D et al. Medical consequences of pathogenic CNVs in adults: analysis of the UK Biobank. J Med Genet. 2019;56:131–8.

[29] Baker K, Costain G, Fung WLA et al. Chromosomal microarray analysis – a routine clinical genetic test for patients with schizophrenia. Lancet Psychiatry. 2014;1:329–31.

[30] Bouwkwamp CG, Kievit AJA, Markx S et al. Copy Number Variation in Syndromic Forms of Psychiatric Illness: The Emerging Value of Clinical Genetic Testing in Psychiatry. Am J Psychiatr. 2017;174:1036–50.

[31] Larson FV, Arrand JR, Tantam D et al. Copy number variants in people with autism spectrum disorders and co-morbid psychosis. Eur J Med Genet. 2018;61:230–4.

[32] Lowther C, Merico D, Costain G et al. Impact of IQ on the diagnostic yield of chromosomal microarray in a community sample of adults with schizophrenia. Gen Med. 2017;9:105.

[33] Thysgesen JH, Wolfe K, Briët ALJ et al. Neurodevelopmental risk copy number variants in adults with intellectual disabilities and comorbid psychiatric disorders. Br J Psychiatry. 2018;212:287–94.

[34] Szatkiewicz JP, Fromer M, Nonneman RJ et al. Characterization of Single Gene Copy Number Variants in Schizophrenia. Biol Psychiatry [Epub ahead of print]. 2019.

[35] Gianitelli M, Consoli A, Raffin M et al. An overview of medical risk factors for childhood psychosis: Implications for research and treatment. Schizophr Res. 2018;192(39):39–49.

[36] Srilakshminarayana V, Harripaul R, Vincent JB et al. Enrichment of pathogenic variants in genes associated with inborn errors of metabolism in psychiatric populations. Am J Med Genet, Part B Neuropsychiatr Genet. 2019;180:46–54.
[37] Bergen SE, Sullivan PF. National-scale precision medicine for psychiatric disorders in Sweden. Am J Med Genet, Part B Neuropsychiatr Genet. 2018;177:630–4.

[38] Dennison CA, Legge SE, Pardiñas AF et al. Genome-wide association studies in schizophrenia: Recent advances, challenges and future perspective. Schizophr Res [Epub ahead of print]. 2019.

[39] Smoller JW. The use of electronic health records for psychiatric phenotyping and genomics. Am J Med Genet, Part B Neuropsychiatr Genet. 2018;177:601–12.

[40] van Os J, Kenis G, Rutten BP. The environment and schizophrenia. Nature. 2010;468:203.

[41] Guloksuz S, Pries LK, Delespaul P et al. Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. World Psychiatry. 2019;18:73–82.

[42] Pries LK, Snijders C, Menne-Lothmann C et al. TwinssCan – Gene-Environment Interaction in Psychotic and Depressive Intermediate Phenotypes: Risk and Protective Factors in a General Population Twin Sample. Twin Res Hum Genet [Epub ahead of print]. 2019.

[43] Caligiuri SP, Kenny PJ. The promise of genome editing for modeling psychiatric disorders. Neuropsychopharmacology. 2018;43:223–4.

[44] Soliman MA, Aboharb F, Zeitner N et al. Pluripotent stem cells in neuropsychiatric disorders. Mol Psychiatry. 2017;22:1241–9.

[45] Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013;381:1371–9.

[46] Cross-Disorder Group of the Psychiatric Genomics Consortium. Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. Cell. 2019;179:469–82.e11.

[47] O’Dushlaine C, Rossin L, Lee PH et al. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat Neurosci. 2015;18:199–209.

[48] Singh T, Walters JTR, Johnstone M et al. The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability. Nat Genet. 2017;49:1167–73.

[49] Miller DT, Adam MP, Aradhya S et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86:749–64.

[50] Besterman AD, Moreno-De-Luca D, Nurnberger JI Jr. 21st-Century Genetics in Psychiatric Residency Training: How Do We Get There? JAMA Psychiatry. 2019;76:231–2.

[51] Butcher NJ, Fung WL, Fitzpatrick L et al. Response to clozapine in a clinically identifiable subtype of schizophrenia. Br J Psychiatry. 2015;206:484–91.

[52] Bassett AS, Lowther C, Merico D et al. Rare Genome-Wide Copy Number Variation and Expression of Schizophrenia in 22q11.2 Deletion Syndrome. Am J Psychiatr. 2017;174:1054–63.

[53] Wither RG, Borlot F, MacDonald A et al. 22q11.2 deletion syndrome lowers seizure threshold in adult patients without epilepsy. Epilepsia. 2017;58:1095–101.

[54] Finucane. Acculturation in Women with Mental Retardation and Its Impact on Genetic Counseling. J Genet Couns. 1998;7:31–47.

[55] Bergen SE, Ploner A, Howrigan D et al. Joint Contributions of Rare Copy Number Variants and Common SNPs to Risk for Schizophrenia. Am J Psychiatr. 2019;176:29–35.

[56] Finucane B, Challman TD, Martin CL et al. Shift happens: family background influences clinical variability in genetic neurodevelopmental disorders. Genet Med. 2016;18:302–4.

[57] Olsen L, Sparsø T, Weinsheimer SM et al. Prevalence of rearrangements in the 22q11.2 region and population-based risk of neuropsychiatric and developmental disorders in a Danish population: a case-cohort study. Lancet Psychiatry. 2018;5:573–80.

[58] Taniguchi S, Ninomiya K, Kushima I et al. Polygenic risk scores in schizophrenia with clinically significant copy number variants. Psychiatry Clin Neurosci [Epub ahead of print]. 2019.

[59] Tansey KE, Rees E, Linden DE et al. Common alleles contribute to schizophrenia in CNV carriers. Mol Psychiatry. 2016;21:1085–9.

[60] Sullivan PF, Owen MJ. Increasing the Clinical Psychiatric Knowledge Base About Pathogenic Copy Number Variation. Am J Psychiatr. 2020;177:204–9.

[61] Bodkin JA, Coleman MJ, Godfrey LJ et al. Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene. Biol Psychiatry. 2019;86:523–35.

[62] Owen D, Bracher-Smith M, Kendall KM et al. Effects of pathogenic CNVs on physical traits in participants of the UK Biobank. BMC Genomics. 2018;19:867.

F. Degenhardt, MD
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, LVR Klinikum Essen, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
franziska.degenhardt@lvr.de